The novel fluorinated 2-nitroimidazole hypoxia probe SR-4554: reductive metabolism and semiquantitative localisation in human ovarian cancer multicellular spheroids as measured by electron energy loss spectroscopic analysis. by Aboagye, E. O. et al.
British Journal of Cancer(1995) 72, 312-318
©O 1995 Stockton Press All rights reserved 0007-0920/95 $12.00
The novel fluorinated 2-nitroimidazole hypoxia probe SR-4554: reductive
metabolism and semiquantitative localisation in human ovarian cancer
multicellular spheroids as measured by electron energy loss spectroscopic
analysis
EO Aboagyel, AD Lewis', A Johnson 2, P Workman 1,3, M Tracy4 and IM Huxham2
'CRC Department ofMedical Oncology, University ofGlasgow, Beatson Laboratories, Switchback Road, Glasgow G61 IBD, UK;
2Division ofMolecular and Cellular Biology, University ofGlasgow, Glasgow G12 8QQ, UK; 3Present address: ZENECA
Pharmaceuticals, Cancer Research Department, Macclesfield SKJO 4TG, UK; 4Life Sciences Division, SRI International, Menlo
Park, California 94025, USA.
Summary The novel fluorinated 2-nitroimidazole SR-4554 is undergoing preclinical development as a
magnetic resonance spectroscopy and imaging probe for hypoxic tumour cells. We have used electron energy
loss spectroscopic analysis (EELS) to show selective reduction and differential subcellular localisation of
SR-4554 in human ovarian multicellular spheroids. SR-4554 was demonstrated to be metabolised by these
A2780 cells under hypoxic but not under normal aerobic cell culture conditions. The EELS technique
illustrated that the relative amount of drug within the cytoplasm of cells from both the inner region (150-160
gm from edge) and outer edge of the spheroid did not differ significantly after an initial 3 h incubation with
drug. In contrast, an 8-fold differential between the amount of drug retained in the cytoplasm (primarily
ribosomes and endoplasmic reticulum) of cells from the inner vs outer regions of the spheroids was observed
following a subsequent 2 h 'chase' culture in drug-free medium. Within cells from the hypoxic region of the
spheroid, SR-4554 was mainly associated with the endoplasmic reticulum, nucleus and the cytoplasmic side of
intracellular vesicles and also to a lesser extent with the nuclear periphery. Interestingly, the drug was only
weakly associated with the mitochondria and plasma membrane of the cells. The characteristics of cellular and
subcellular distribution of SR-4554 are consistent with the hypothesis that 2-nitroimidazole compounds
undergo hypoxia-mediated enzymatic reduction to reactive species. These reactive species are selectively
retained in the cells in which they are metabolised through covalent association with subcellular components.
These findings provide additional support for the clinical development of the drug as a non-invasive probe for
tumour hypoxia and at the same time illustrate the utility of the EELS technique for examining the
heterogeneity of drug distribution both between and within cells.
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Human and animal tumours have been reported to contain
regions of low oxygen tension or hypoxia (Thomlinson and
Gray, 1955; Moulder and Rockwell, 1984; Rampling et al.,
1994). Tumour cells existing under hypoxia may be more
resistant to therapy for a variety of reasons. These factors
include: the requirement for molecular oxygen in the fixation
of radiation-induced radicals and drug-induced damage, and
certain drug activation processes; non-cycling cell kinetics;
and decreased drug uptake (Workman, 1991). In recent years
strategies have been developed to identify hypoxic cells
within tumours, in order to facilitate the rational selection of
appropriate therapeutic regimens. In this regard, both sur-
gically invasive and non-invasive techniques such as auto-
radiography, immunohistochemistry, magnetic resonance
spectroscopy (MRS) and single positron emission tomo-
graphy (SPET) have been used to provide a clinically
relevant approach to identifying these hypoxic cells within
tumours (Chapman, 1984; Maxwell et al., 1988; Koh et al.,
1991; Kwock et al., 1992; Lord et al., 1993; Hodgkiss et al.,
1994; Raleigh et al., 1994).
Nitroimidazoles, including misonidazole, have been under
evaluation as potential diagnostic probes for hypoxic cells.
This is because of the specific reductive metabolism of the
drugs to reactive metabolites which bind to macromolecules
within hypoxic cells (Miller et al., 1982; Chapman et al.,
1983). The characteristics of binding have been evaluated in
various cell lines and tumours, although the exact nature of
the metabolite is not known (Miller et al., 1982; Chapman et
al., 1983). Interestingly, previous subcellular fractionation
studies in EMT6 cells with ['4C]misonidazole have indicated
that 77% and 23% of the total activity is associated with the
acid-insoluble (bound) and the acid-soluble fractions (un-
bound) respectively (Miller et al., 1982). Further, the acid-
insoluble fraction is distributed among RNA (17%), DNA
(1%), lipid (4%) and protein (1%) (Miller et al., 1982). In
another study by the Edmonton group, the involvement of
intracellular enzymes in the activation process was imp-
licated, since the temperature dependence of this process
showed an activation energy of 33.5 kcal mol' (Chapman et
al., 1983). This study also demonstrated that the binding rate
of misonidazole within hypoxic cells was at least 50 times
greater than within aerobic cells, and suggested that the
activation sites may be lipid associated. The higher rate of
binding and longer half-life of the bound metabolite com-
pared with the parent unmetabolised compound are con-
sidered as favourable characteristics with regard to the use of
2-nitroimidazoles as possible markers for hypoxic cells.
Electron energy loss spectroscopic analysis (EELS) by elec-
tron spectroscopic imaging (ESI) is an emerging technique
for the in situ examination of objects and compounds in cells
and tissues, but has only recently been applied to an analysis
of cancer therapeutic compounds (Huxham et al., 1992,
1993). Briefly, the technique relies upon measurement of the
electron energy distribution of transmitted electrons that
have lost energy following interaction with a specimen. This
is done by recording an energy spectrum as a sequence of
images with high spatial resolution. These filtered electron
image sequences contain information about the element-
specific energy loss population (equivalent to energy loss
edge) superimposed on the non-specific energy loss popula-
tion (equivalent to background). Data are processed mathe-
matically to obtain edge intensity information which relates
directly to the elemental concentration of the specimen. Com-
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study, can thus disclose semiquantitative elemental inform-
ation on a local (nm) scale.
In the present investigation, we used energy electron loss
spectroscopy to study the localisation of a novel fluorinated
2-nitroimidazole SR-4554 (Figure 1) within A2780 human
ovarian multicellular spheroids. The A2780 spheroid model
was chosen because it provides the coexistence of both
aerobic and hypoxic cells under normal aerobic cell culture
conditions, allowing manipulations on both types of cells to
be carried out simultaneously. Moreover, we have previously
used this spheroid model with EELS (Huxham et al., 1992,
1993) to assess the localisation of fluorine-containing drug
bound to macromolecules within different cell populations
and subcellular compartments. SR-4554 was designed to con-
tain three equivalent fluorines within *a metabolically stable
side-chain of appropriate lipophilicity, while retaining a
similar reduction potential to misonidazole. Currently, SR-
4554 is undergoing preclinical evaluation as a non-invasive
probe for tumour hypoxia by fluorine-based magnetic
resonance spectroscopy (MRS) and imaging (MRI). Together
with bioreductive metabolism studies which are reported
here, the present localisation studies will help in our under-
standing of the characteristics of metabolism-induced binding
of SR-4554 and of 2-nitroimidazoles in general.
Materials and methods
Metabolism studies
SR-4554 [N-(2-hydroxy-3,3,3 trifluoropropyl)-2-(2-nitro-1-imi-
dazolyl) acetamide] was synthesised and supplied by SRI
International, Menlo Park, CA, USA. A2780 cells were cul-
tured as monolayers in RPMI medium (Life Technology,
Paisley UK) supplemented with 10% (v/v) fetal calf serum
(Globepharm, Esher, Sussex, UK), and 0.001% (w/v) insulin
(Lewes, Sussex, UK). The cells were grown to near
confluence, trypsinised and plated at a concentration of
5 x 10 cells ml-' in 5 ml. Cells were allowed to adhere to the
flasks and the medium replaced with one containing 10 and
20"lM SR-4554. The flasks were then incubated for various
lengths of time up to 3 h under hypoxic (98% nitrogen and
2% carbon dioxide) or aerobic (2% carbon dioxide and 20%
oxygen in nitrogen) conditions. Drug-containing media
obtained at 0, 0.5, 1, 2, 3 h were then analysed by high-
performance liquid chromatography (HPLC).
HPLC analysis and rate ofSR-4554 reduction
Aliquots (2501l) of the incubation media were spiked with
20 tl of an internal standard (8 tg ml1' Ro 07-0269 [1-(2-
nitro-l-limidazolyl)-3-chloro-2-propanol] supplied by Roche,
Welwyn Garden City, Herts, UK) and the mixture extracted
with 25 LIl of silver nitrate solution (30%, w/v). Samples were
vortexed, centrifuged (at 1000g) for Omin, and the super-
natants analysed by HPLC (Millipore UK Ltd, Watford,
UK) using a C,8,uBondapak analytical column and a mobile
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Figure 1 Drug structure of SR-4544.
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phase consisting of 15% methanol and water. The analytes
were eluted at a flow rate of 2ml min-', and the column
effluent monitored at a wavelength of 324 nm. Calibration
standards (0.35-35.46ILM) were prepared in RPMI medium
and analysed under identical conditions to that above. The
concentrations of parent drug in the incubation samples were
determined and plotted against time. Rates of reduction were
estimated from the initial slope of the concentration of SR-
4554 vs time curve, which was linear within the time period
studied.
Spheroid culture and EELs analysis
Human ovarian A2780 cells were plated (in RPMI medium)
at a concentration of 2 x 106 cells 50ml-' and incubated in
stirrer flasks at 37°C to form spheroids. After 3.5 days in
culture, spheroids of approximately 0.8-1.4 mm in diameter
were obtained for use in the EELS experiment. Initially the
spheroids formed as aggregates, but after 3.5 days in culture
they formed tight proliferating spheroids. Under these condi-
tions the large spheroids develop a region of hypoxia
between the outer cells and the necrotic core. For the present
experiments, the outer most cell layer of the spheroid was
taken to be aerobic, whereas cells in the inner region of the
spheroid, at approximately 150-160iLm from the surface,
but separate from any necrotic core, were selected as hypoxic
as shown by Miller et al. (1989) using EMT6 spheroids.
A2780 spheroids are similar to EMT6 spheroids in that both
form tight spheroid structures. In this regard, spheroid
models showing differences in oxygen levels and binding of
2-nitroimidazoles have previously been established (Franko et
al., 1987; Franko et al., 1992).
The spheroids were incubated with culture medium con-
taining a non-toxic concentration of 1 mM SR-4554 at 37°C
for 3 h. Incubations were carried out under normal aerobic
cell culture conditions. Half of the spheroids were then trans-
ferred onto ice to stop further reaction. The other half were
washed with fresh culture medium and 'chased' at 37°C for
2 h under normal aerobic conditions. These were also trans-
ferred onto ice to stop further reaction.
For analytical electron microscopy, all spheroids were
briefly washed in phosphate-buffered saline (PBS), and
chemically fixed (on ice) with 1% glutaraldehyde in PBS for
1.5 h. The spheroids were dehydrated in a series of alcohols
for embedding at low temperature in Lowicryl K4M, a
nitrogen-free hydrophilic methacrylate resin, without the use
of heavy metal stains to avoid electron scattering. Ultrathin
sections were mounted onto 700 mesh copper grids for elect-
ron spectroscopic analysis using a Zeiss TEM902 microscope
(Karl Zeiss Oberkochen, Oberkochen, Germany) operating at
80 kV and 12 000 x magnification. The microscope was fitted
with an electron energy filter for analysis of the local electron
energy associated with fluorine (K-edge onset at AE = 688
eV) and nitrogen (K-edge onset at AE = 405 eV). This novel
technique has a resolution of about 2 nm and an energy
resolution of about 5eV (Huxham et al., 1992; Johnson et al.,
1995) for sections of resin-embedded cells, and a theoretical
detection limit for fluorine of about 500 atoms.
Energy-filtered image sequences were recorded between
AE = 650 and 750 eV for fluorine and between AE = 350
and 450 eV for nitrogen, changing only the (measurable)
video-camera (Dage SIT, Michigan, MN, USA) kV setting
between each sequence pair to accommodate the change in
energy loss intensity relative to the dynamic range of the
video-camera. Comparisons between defined regions within
peripheral (outer) cells and cells approximately 150-160plm
from the edge of the spheroid (inner cells) were made using
in-house software.
Energy loss contributions of both fluorine and nitrogen
were measured following background modelling for each
pixel in median filtered energy loss image sequence. This was
accomplished using the least mean square determination of
the parameters which describe the energy loss curve (deBruijn
et al., 1993; Johnson et al., 1995). Cumulative background-
stripped grey level values from 12 image sequences over a 30Localisaflon of a 2-nitroimidazole hypoxia probe in human spheroids
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eV portion of the post-ionisation edge for fluorine and nit-
rogen were used to calculate elemental ratios. In this way,
variations in the density of cellular material between one
domain and another could be normalised as a function of the
nitrogen content for each region of interest, to produce local
semiquantitative elemental maps. Data were also expressed as
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average grey level value representing energy loss for fluorine
as a function of section area for each pixel.
Results
Metabolism ofSR-4554 by human ovarian carcinoma cells
SR-4554 was reduced by A2780 cells in culture under
hypoxic conditions. This was assessed by chromatographic
analysis of loss of parent drug metabolised by the cells in
culture. Figure 2 shows a typical chromatogram of a hypoxic
compared with an aerobic incubation sample also containing
the internal standard (Ro 07-0269). No metabolites were
observed. The rates of reduction of SR-4554 by A2780 cells
under aerobic and hypoxic culture conditions are shown in
Table I. These data, obtained only at 37°C, demonstrated the
selective reduction of SR-4554 under hypoxia in contrast to
normal aerobic conditions. As expected, the reduction rates
increased with increasing substrate concentration.
Localisation ofSR-4554 within human ovarian carcinoma cells
by EELS
EELS analysis of spheroids incubated with SR-4554 enabled
the localisation of the fluorine atoms in subcellular com-
ponents as well as across different regions within the
spheroid. Figure 3 shows an unstained, energy filtered image
(reversed contrast) of A2780 cells from a spheroid after
culture in SR-4554-containing medium, recorded at
AE = 150 eV. By means of spectroscopic imaging, most
intracellular structures of unstained material, otherwise
difficult to see without filtering, could be identified for
analysis. Using our in-house image analysis software, regions
of interest (ROI) for each electron spectroscopic image
sequence (ESIS) were defined simply by drawing on the
Table I Rate of loss of SR-4554 incubated with A2780 cells
Rate ofloss
Conditions Drug concentration (tM) (nmolh-' 10-6 cells)
Aerobic 20 No loss detected
10 No loss detected
Hypoxic 20 7.54 0.10
10 4.32 0.25
SR4554 was incubated with A2780 cells under aerobic and hypoxic
conditions. The levels of parent drug remaining at various time
periods were determined as described in the Materials and methods
section. The values for rate of loss of compound are means ± s.d.
from at least three separate determinations.
Time (min)
Figure 2 Typical HPLC plot of SR-4554 after incubation with
A2780 cells for 30 min under (a) aerobic and (b) hypoxic condi-
tions. The conditions of HPLC were as described in the Materials
and methods section. From left to right the three peaks illus-
trated indicate the solvent front, SR-4554 and internal standard
(IS; Ro 07-0269) respectively.
Figure 3 Energy-filtered image of a portion of a heavy metal-
free A2780 cell within SR-4554-treated multicellular spheroids
after a 'chase' culture, recorded at AE = 150eV, showing
enhanced contrast in phosphorus-rich regions. The image shows a
well-defined nuclear region (N), nuclear membrane (arrow),
mitochondria (M) and a cytoplasmic region rich in polyribosomes
(PR). Bar = 600 nm.
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reference image on the display screen. The same ROI was
used for analysis of both nitrogen and fluorine ESIS
sequences. The energy losses for nitrogen and fluorine were
then determined by plotting the cumulative grey level value
for the ROI for each ESIS. A representative projected dist-
ribution of fluorine (green) within a section of the inner
region of the spheroid after the 'chase' process is shown in
Figure 4. This represents residual bound drug within the cell.
An analysis of cytoplasmic domains (which includes cytop-
lasm, mitochondria, vesicle periphery and plasma membrane
regions) of cells within A2780 spheroids (Figure 5) suggest
that the drug was distributed into cells across the whole
spheroid after a 3 h culture. Following chemical fixation of
these spheroids, only marginally less drug was bound to
intracellular components within cells of the inner region of
the spheroid as compared with the equivalent components of
cells in the outer region. More importantly, an 8-fold higher
level of drug was present within the cytoplasmic domains of
these inner cells after 'chasing' with drug-free media, as most
of the drug which was present in the outer cells had diffused
31
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Figure 4 (a) Reference image of a section from an inner A2780 cell within SR-4554-treated multicellular spheroids after a 'chase'
culture, recorded AE = 150eV. The image shows the plasma membrane (PM), vesicles (V), cytoplasm (C); nuclear membrane
(NM), nucleus (N) and nucleolus (Nclo). (b) The same image upon which the projected fluorine distribution is superimposed
(green). The green binary fluorine map simply shows regions in which fluorine was found to be present (i.e. a stripped grey level
value above background). TIFF images were reproduced on a Kodak Colourease printer (field width = 5pm).Localisation of a 2-nitroimidazole hypoxia probe in human spheroids
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away following the 'chase' process. This selective retention of
drug by the inner cells is indicative of increased bioactivation
within the inner cells of the spheroids.
Table II demonstrates that the drug distribution present
within the cells from both the inner and outer regions of
'chased' spheroids was not uniform. Relative to the intrinsic
nitrogen content of specific intracellular regions, which takes
into account local variations in biological material, the
amount of drug within the inner cells was found to be
comparatively high at the periphery of intracellular vesicles,
within the cytoplasm, in the nucleus and at its periphery. In
contrast, the amount of drug was comparatively low within
mitochondria and at the plasma membrane. Although the
nitrogen atoms in the drug will contribute to the total nit-
rogen intensity signal of the EELS technique, by far the
greater contribution will come from the biological mac-
romolecules of the cell to which the drug is localised. When
simply expressed in terms of the average amount of fluorine
per unit area ofcell section, the data suggested that there was
a relative accumulation of fluorine at the nuclear periphery
and in the nucleus compared with other regions, more
representative of the projected fluorine distribution shown in
Figure 4. In contrast, and as expected, across all domains
there was less drug (3 to 10-fold) localised within the outer
cells than in the inner cells.
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Figure 5 Histograms showing the mean ± s.d. of fluorine/
nitrogen (F/N) elemental ratios for cytoplasmic domains (which
includes cytoplasm, mitochondria, vesicle periphery and plasma
membrane regions) from the outer and inner cells of A2780
multicellular spheroids cultured for 3 h (O) in SR-4554 and after
a 2 h 'chase' culture (0) in drug-free media. Using the
Mann-Whitney U-test (non-parametric), a significant difference
was determined between the outer and inner cells after the 'chase'
period (P < = 0.05).
Discussion
The localisation of 2-nitroimidazoles following reduction by
tumour cells is important in our understanding of the use of
these compounds as hypoxic probes. The human ovarian
A2780 cell line was used in this study since this cell line has
previously been shown to express cytochrome P450 reduc-
tase, an enzyme involved in the reductive metabolism of
2-nitroimidazoles, by enzyme assay and PCR analysis (data
not shown). This cell line was also considered likely to
develop a hypoxic region in spheroids over the size range
used.
The characteristics of the metabolism-induced binding of
2-nitroimidazoles to macromolecules in hypoxic tissue are
still not fully understood. In particular, the nature of the
drug adducts and the subcellular localisation of these com-
pounds has been poorly addressed in the literature to date.
This paper addresses some of these issues with respect to the
use of a novel fluorinated 2-nitroimidazole (SR-4554) in
A2780 cells/spheroids and the application of the EELS tech-
nique. However, these results are also relevant to the action
of other 2-nitroimidazoles. The structure of SR-4554 is based
on that ofetanidazole (Brown and Workman, 1980), while its
lipophilicity is more similar to misonidazole. The lipo-
philicities for SR-4554, etanidazole and misonidazole being
0.634, 0.046, and 0.430 respectively. Interestingly, the dis-
tribution properties demonstrated in our study are more
appropriate in terms of those of etanidazole-like oxygen-
dependent binding of the compound rather than mison-
idazole (Workman, 1982; Franko et al., 1987; Kocha et at.,
1993). As expected, SR-4554 was metabolised (reduced) selec-
tively by hypoxic A2780 cells but not under aerobic condi-
tions.
The use of the novel EELS technique permitted the
localisation of the compound within human ovarian car-
cinoma spheroids. In cultures not subjected to 'chasing', no
significant differential was observed between cells of the inner
and outer regions of the spheroid. This presumably is due to
the presence of both original parent drug and bound drug
metabolites. Since the EELS technique maps only atoms such
as fluorine, nitrogen and phosphorus it cannot distinguish
between original parent and bound drug. The method of
'chasing' in drug-free media to differentiate between bound
and unbound drug was, therefore, employed to allow the
assessment and localisation of bound metabolites. Interest-
ingly, the results we obtained in our study using spheroids
and EELS were in accordance with metabolism-induced bin-
ding of 2-nitroimidazoles to macromolecules as previously
demonstrated by other methods with limited spatial resolu-
tion such as autoradiography and immunohistochemistry
(Miller et al., 1982; Lord et al., 1993). In contrast to these
other methods, the EELS technique also has the ability to
measure drug binding relation to the density of other local
macromolecular components. Although some non-specific
binding occurred in the cells of the outer (aerobic) region of
Table II The relative average fluorine and fluorine/nitrogen elemental ratios for six intracellular domains ofboth outer
and inner cells from A2780 multicellular spheroids following culture with SR-4554
Nuclear Vesicle Plasma
Domain Nucleus periphery Cytoplasm Mitochondria periphery membrane
F/N ratio
Outer 0.03 ± 0.02a 0.03 ± 0.01 0.11 ± 0.04 NDb 0.07 ± 0.03 ND
Inner 0.21 ± 0.02 0.25 ± 0.08 0.29 ± 0.08 0.06 ± 0.02 0.31 ± 0.06 0.16 ± 0.05
F/pixel
Outer 0.65 ± 0.28 0.45 ± 0.19 0.75 ± 0.22 ND 0.61 ± 0.18 ND
Inner 2.15 0.55 4.25 0.75 1.97 0.46 0.85 ± 0.22 0.25 0.06 0.49 ± 0.13
aAverage value from 12 areas ± s.d. for each domain expressed as the relative amount of fluorine per pixel (8 nm2)
(F/pixel) or as a fluorine to nitrogen ratio (F/N ratio) in arbitary units.
bND, not detected. Mann-Whitney U-test 5% significance: forF/Nratio: outer cells, cytoplasm vs nuclear periphery and
cytoplasm vs nucleus; inner cells, vesicle periphery vs mitochondria and vesicle periphery vs plasma membrane,
mitochondria vs nucleus, mitochondria vs nuclear periphery and mitochondria vs cytoplasm. For F/pixel: outer cells, no
significant differences observed; inner cells, mitochondria vs nucleus and mitochondria vs nuclear periphery, nuclear
periphery vs cytoplasm, nuclear periphery vs vesicle periphery and nuclear periphery vs plasma membrane.
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the spheroids, levels offluorine in the cytoplasm ofcells from
the inner (hypoxic) regions were 8-fold higher. This effect is
the more likely to occur in vivo, where elimination processes
will result in the removal of unbound drug compared with
the bound metabolite. Importantly, the localisation charac-
teristics shown in our study are very relevant to the use of
this novel fluorinated compound as a non-invasive marker of
tumour hypoxia in the clinic. The presence of three
magnetically equivalent fluorine atoms in the structure of the
compound, which remains intact on enzyme reduction, is
important in terms of its detection by resonance techniques
as well as by EELS.
Further studies using EELS enabled us to analyse in more
detail the subcellular localisation of the compound within
cells of both the outer and inner region of the spheroid. In
our study, the mitochondria and plasma membrane did not
appear to bind significant amounts of drug. Of interest,
however, were the high levels of the compound localised to
the nuclear periphery, nucleus and cytoplasm within the inner'
cells. These data are in agreement with previous published
studies using subcellular fractionation of cells labelled with
['4C]misonidazole (Miller et al., 1982), considering that the
molecular components in these regions consist mainly of
RNA, DNA, lipids and proteins. In addition, the distribution
of 2-nitroimidazole to cytoplasm, nuclear and perinuclear
regions was also mentioned by Cline et al. (1994), who used
antibodies against CCI-103F/CCI-103F adducts to follow the
distribution of hypoxia and/or reductive enzymes within cells
of canine tumours. In contrast, and as expected, less drug
was distributed within all the domains in the outer cells.
The initial steps in the reductive metabolism of 2-
nitroimidazoles are mainly catalysed by cytochrome P450
reductase and to a lesser extent cytochrome P450, both of
which are found in the endoplasmic reticulum (McManus et
al., 1982; Walton and Workman, 1987). The subcellular dist-
ribution of the SR-4554 compound demonstrated in our
study suggests that the reactive intermediate is short-lived
and binds to macromolecules within the vicinity of the
metabolism site or to nucleophiles such as RNA close to
these sites. Importantly, the evidence would suggest that the
reactive metabolites do not appear to migrate out of the cells.
This characteristic is also relevant to the design of bioreduc-
tive drugs, based on 2-nitroimidazoles, which will target the
nucleus of the cell to deliver radioisotopes or alkylating
moieties.
Currently, SR-4554 is undergoing preclinical development
before scheduled clinical trials as a probe for investigating
tumour hypoxia by non-invasive MRS. Important to the
direction of these studies, this paper describes the intracel-
lular distribution of the compound within hypoxic regions of
human ovarian carcinoma spheroids and is useful in the
interpretation of data from MRS studies. In addition, how-
ever, the EELS technique itself can also be used to study the
distribution of hypoxic regions within tumours labelled in
vivo with SR-4554, even though this will involve invasive
(biopsy) procedures. As a semiquantitative technique,
moreover, it offers the potential of measuring hypoxia on a
cell-to-cell basis at a molecular level with good resolution
compared with antibody techniques and also the investiga-
tion ofdrug to macromolecule interactions without the use of
radioisotopes.
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